Health and Fitness Health and Fitness
Mon, October 25, 2010
[ Mon, Oct 25th 2010 ] - Market Wire
Orthofix International to Participate in Oppenheimer 21st Annual Healthcare Conference
[ Mon, Oct 25th 2010 ] - Market Wire
Alkermes Announces Positive Results from Phase 1 .. on with Buprenorphine for Treatment of Cocaine Ad
[ Mon, Oct 25th 2010 ] - Market Wire
Helicos BioSciences Amends Patent Infringement La .. ciences to Include Illumina and Life Technologies
[ Mon, Oct 25th 2010 ] - Market Wire
Emeritus to Acquire Rehab Therapy Services Group
[ Mon, Oct 25th 2010 ] - Market Wire
Seattle Genetics and Millennium to Highlight Bren .. t the International Symposium on Hodgkin Lymphoma
[ Mon, Oct 25th 2010 ] - Market Wire
BioCryst to Present at Oppenheimer Healthcare Conference
[ Mon, Oct 25th 2010 ] - Market Wire
Bestuur Alcon kiest nieuwe voorzitter
[ Mon, Oct 25th 2010 ] - Market Wire
AngioDynamics to Participate at the 21st Annual Oppenheimer Healthcare Conference
[ Mon, Oct 25th 2010 ] - Market Wire
Junta de Alcon elige nuevo presidente
[ Mon, Oct 25th 2010 ] - Market Wire
Il Consiglio di amministrazione di Alcon nomina il suo nuovo Presidente
[ Mon, Oct 25th 2010 ] - Market Wire
Conselho da Alcon elege novo presidente
[ Mon, Oct 25th 2010 ] - Market Wire
Alcon-Verwaltungsrat whlt neuen Vorsitzenden
Sun, October 24, 2010
[ Sun, Oct 24th 2010 ] - Market Wire
Gileada?s Cayston® superieur aan Tobramycine inh .. anden durende head-to-head cystic fibrosis studie
[ Sun, Oct 24th 2010 ] - Market Wire
Alcon Board Elects New Chairman
[ Sun, Oct 24th 2010 ] - Market Wire
HERBALIFE LANZA NUEVOS PRODUCTOS INCLUYENDO BATID .. EINA SIN ALERGENOS Y SUPLEMENTO NUTRICIONAL COQ10
Sat, October 23, 2010
[ Sat, Oct 23rd 2010 ] - Market Wire
Dr. Reddya?s Q2 FY11 Financial Results
Fri, October 22, 2010
[ Fri, Oct 22nd 2010 ] - Market Wire
Cayston® von Gilead zeigt in sechsmonatiger Kopf .. Fibrose berlegenheit gegenber Tobramycin-Inhalat
[ Fri, Oct 22nd 2010 ] - Market Wire
Cayston® di Gilead si dimostrato superiore alla .. alazione in uno studio di raffronto diretto della
[ Fri, Oct 22nd 2010 ] - Market Wire
Law Offices of Howard G. Smith Announces Investig .. rs of Clarient, Inc. in Connection with the Propo
[ Fri, Oct 22nd 2010 ] - Market Wire
MannKind Corporation to Hold 2010 Third Quarter F .. ncial Results Conference Call on October 29, 2010
[ Fri, Oct 22nd 2010 ] - Market Wire
Sycamore Entertainment Group Launches New Corporate Website
[ Fri, Oct 22nd 2010 ] - Market Wire
Faruqi & Faruqi, LLP Announces Investigation Related to the Acquisition of Clarient Inc. a" CLRT
[ Fri, Oct 22nd 2010 ] - Market Wire
Clarient, Inc. Shareholder Investigation by Brisc .. Regarding the Buyout by General Electric Company
[ Fri, Oct 22nd 2010 ] - Market Wire
Cardiac Science Shareholder Investigation by Bris .. ing the Merger with Opto Circuits (India) Limited
[ Fri, Oct 22nd 2010 ] - Market Wire
Kendall Law Group Investigates Clarient, Inc. Acquisition for Shareholders
[ Fri, Oct 22nd 2010 ] - Market Wire
Health Net Federal Services Awarded Department of .. ns Affairs CBO Outpatient Recovery Audit Contract
[ Fri, Oct 22nd 2010 ] - Market Wire
Wright Medical Group, Inc. Announces Full Commerc .. f PRO-STIMa" Osteoinductive Bone Graft Substitute
[ Fri, Oct 22nd 2010 ] - Market Wire
St. Jude Medical Board of Directors Authorizes Share Repurchase
[ Fri, Oct 22nd 2010 ] - Market Wire
Biogen Idec en Genentech melden herstructurering anti-CD20 samenwerkingsovereenkomst
[ Fri, Oct 22nd 2010 ] - Market Wire
Biogen Idec y Genentech anuncian modificacin en su acuerdo de colaboracin de anticuerpos anti-CD20

Biogen Idec y Genentech anuncian modificacin en su acuerdo de colaboracin de anticuerpos anti-CD20


Published on 2010-10-22 04:06:01 - Market Wire
  Print publication without navigation


WESTON, Massachussets & SOUTH SAN FRANCISCO--([ BUSINESS WIRE ])--[ Biogen Idec ] (Nasdaq: BIIB) y [ Genentech, Inc. ] filial propiedad al 100% de [ Roche Group ] (SIX: RO, ROG; OTCQX: RHHBY) han suscrito un contrato para modificar su colaboracin respecto a los anticuerpos anti CD20. Las empresas han acordado que Genentech ser el responsable del futuro desarrollo de ocrelizumab en esclerosis mltiple (MS en sus siglas en ingl©s). Genentech financiar el 100% de los costes relacionados con el proceso y ser responsable del desarrollo y comercializacin. Biogen Idec percibir royalties de dos dgitos de las ventas estadounidenses de ocrelizumab que se aproximarn a su participacin actual del 30% en el compuesto. Adems, las empresas han acordado que la comercializacin de ocrelizumab no repercutir en la actual cuota de beneficios de [ RITUXAN® ] (rituximab).

El comunicado en el idioma original, es la versin oficial y autorizada del mismo. La traduccin es solamente un medio de ayuda ydeber sercomparada con el texto en idioma original, que es la nica versin del texto que tendr validez legal.

Contributing Sources